Value and price of ventilator-associated pneumonia surveillance as a quality indicator
Aardema, Heleen; Dijkema, L. Marjon; Lazonder, Mark G.; Ligtenberg, Jack J. M.; Tulleken, Jaap E.; Zijlstra, Jan G.

Published in:
Critical Care

DOI:
10.1186/cc8189

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2010

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Value and price of ventilator-associated pneumonia surveillance as a quality indicator

Heleen Aardema, L Marjon Dijkema, Mark G Lazonder, Jack JM Ligtenberg, Jaap E Tulleken and Jan G Zijlstra*

Awareness of the importance of quality assurance in the ICU is growing but the methodology is still under development and subject to debate [1-3]. Ventilator-associated pneumonia (VAP) seemed to come close to being an important, valid, reliable, responsive, interpretable and feasible outcome parameter [3]. We therefore decided to measure VAP incidence on a regular basis. A prospective study was carried out with yearly assessment of the incidence of VAP during a 3-month period. Definition of VAP was based on the recommendations of the Centers for Disease Control and Prevention [4]. Overall, out of 550 patients ventilated for >48 hours, only two cases of definite VAP were observed [5]. Because no further improvement could be achieved in this field, we turned our attention to other outcome parameters. A perceived rise in incidence of VAP led us to repeat our evaluation, despite growing concern about the importance, validity and reliability of VAP as a quality indicator [2].

With the same methodology we measured the incidence of VAP again. Compared to our previous research, we observed a significant ($P < 0.001$, chi-square test) increase in VAP in accordance with our impressions (Table 1).

The incidence of VAP in our unit is still below that reported in the literature [2]. When used as a benchmark, we are performing well. However, when used as a quality indicator over time the results should lead to concern. Even if patients diagnosed with VAP do not have real VAP but colonisation, atelectasis, or fluid overload, these conditions are also detrimental for the patient and should be avoided [2].

As a benchmark, VAP incidence might have limited value [1,2]. This is mainly due to inappropriate case mix correction and to diagnostic inaccuracy. Fear of being judged on disputable quality indicators such as inter-hospital benchmarks is a serious threat to the probably valuable use of intra-hospital trend analysis of quality indicators. Used as a longitudinal quality indicator in a single centre, VAP is less threatened by case-mix differences and the limited sensitivity and specificity of the VAP diagnostic criteria. The price of this quality assessment is considerable. The workload of this 14-week evaluation resulted in an estimated cost of 20,000 euros.

In our view, measurement of VAP incidence has its value as an intra-hospital quality indicator but not as a benchmark.

Table 1. Patients characteristics and results

| Patients ventilated >48 hours (n) | 169 |
| Male:female | 110:59 |
| Medical ICU (n) | 49 |
| Surgical ICU (n) | 55 |
| Neuro-surgical ICU (n) | 29 |
| Cardio-thoracic ICU (n) | 36 |
| Age, years, median (range) | 60 (21-84) |
| APACHE II score, median (range) | 19 (12-36) |
| Length of ICU stay, days, median (range) | 12 (2-103) |
| Ventilator days, median (range) | 7 (2-91) |
| VAP, definite (n)* | 15 |
| VAP, probable (n)* | 12 |
| Definite VAP per 1,000 ventilator days (n) | 7.5 |
| Percentage patients with definite VAP (%) | 8.9% |
| ICU mortality, n (%) | 34 (20%) |
| Mortality in patients with definite VAP, n (%) | 2 (13%) |

*Defined as based on Centers for Disease Control and Prevention criteria [4]; all the same circumstances as above except a positive culture as the required parameters. VAP, ventilator-associated pneumonia.

Abbreviations

VAP = ventilator-associated pneumonia.

Acknowledgements

All participating physicians for the recording of data, Mr H van Assen for providing all APACHE-scores of included patients.
Competing interests
The authors declare that they have no competing interests.

Published: 4 February 2010

References

doi:10.1186/cc8189
Cite this article as: Aardema LM, et al: Value and price of ventilator-associated pneumonia surveillance as a quality indicator, Critical Care 2010, 14:403.